Allogene Therapeutics
ALLO
160 hedge funds and large institutions have $208M invested in Allogene Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 53 increasing their positions, 45 reducing their positions, and 27 closing their positions.
38% more call options, than puts
Call options by funds: $223K | Put options by funds: $162K
18% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 45
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
6% less funds holding
Funds holding: 171 → 160 (-11)
6.78% less ownership
Funds ownership: 90.73% → 83.95% (-6.8%)
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
69% less capital inflows, than outflows
Capital inflows: $8M | Capital outflows: $26.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.66M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.24M |
| 3 |
Primecap Management
Pasadena,
California
|
+$1.05M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$579K |
| 5 |
Graham Capital Management
Rowayton,
Connecticut
|
+$402K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.52M |
| 2 |
JP Morgan Chase
New York
|
-$5.58M |
| 3 |
Morgan Stanley
New York
|
-$2.32M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$1.48M |
| 5 |
Jane Street
New York
|
-$936K |
ALLO Hedge Fund Activity: Q2 2025 in Review
160 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2025, worth a combined $208M — down 31% from $302M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ALLO and 18 opened new positions — a net loss of 9 holders — while 45 trimmed existing stakes and 53 added.
The largest buyer was Millennium Management, adding an estimated $1.66M. The largest seller was Fidelity Investments, cutting an estimated $8.52M.
- 160 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2025, down from 171 in Q1 2025.
- Funds reported $208M of Allogene Therapeutics stock for Q2 2025, down 31% quarter-over-quarter.
- 18 funds opened new Allogene Therapeutics positions in Q2 2025 and 27 closed out, a net change of -9 holders.
- The largest Allogene Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $1.66M added.
- The largest Allogene Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $8.52M sold.
Based on aggregated 13F filings for Q2 2025.